Encorafenib
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E. The drug was developed with the hypothesis that a more potent RAF inhibitor with superior pharmacological properties would maximize the degree and duration of patient response. In preclinical studies, oral dosing of encorafenib resulted in potent and sustained inhibition of the RAS/RAF/MEK/ERK pathway.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 encorafenib : Melanoma
19 encorafenib : Colorectal cancer (CRC)
LIST OF FIGURES
11 Figure 1: Encorafenib for melanoma – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of encorafenib for melanoma
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of encorafenib for melanoma
15 Figure 4: Encorafenib sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
24 Figure 5: Encorafenib for colorectal cancer – SWOT analysis
25 Figure 6: Datamonitor Healthcare’s drug assessment summary for encorafenib in colorectal cancer
26 Figure 7: Datamonitor Healthcare’s drug assessment summary for encorafenib in colorectal cancer
28 Figure 8: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Encorafenib drug profile
8 Table 2: Encorafenib Phase III data in melanoma
10 Table 3: Encorafenib Phase II trial in melanoma
16 Table 4: Encorafenib sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
18 Table 5: Encorafenib patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
19 Table 6: Encorafenib drug profile
21 Table 7: Encorafenib Phase III data in colorectal cancer
23 Table 8: Encorafenib Phase II data in colorectal cancer
29 Table 9: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
31 Table 10: Patients treated with encorafenib across the US and five major EU markets, by country, 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Zelboraf 
Sign up to the